Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 19/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 9/20 | 1.00 |
| ▸ | MAPK3 | P27361 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | MAPK6 | Q16659 | 1/20 | 1.00 |
| ▸ | INSR | P06213 | 3/20 | 0.74 |
| ▸ | KDR | P35968 | 2/20 | 0.71 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.71 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.71 |
| ▸ | LATS1 | O95835 | 1/20 | 0.71 |
| ▸ | LCK | P06239 | 1/20 | 0.71 |
| ▸ | LYN | P07948 | 1/20 | 0.71 |
| ▸ | RET | P07949 | 1/20 | 0.71 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.71 |
| ▸ | MET | P08581 | 1/20 | 0.71 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.71 |
| ▸ | INSRR | P14616 | 1/20 | 0.71 |
| ▸ | FECH | P22830 | 1/20 | 0.71 |
| ▸ | MARK3 | P27448 | 1/20 | 0.71 |
| ▸ | FLT4 | P35916 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1315173 | 1.00 | IGF1R (1.00) | IGF1RCYP3A4MAPK3MAPK1MAPK6 | |
| SCHEMBL400255 | 1.00 | IGF1R (1.00) | IGF1RCYP3A4MAPK3MAPK1MAPK6 | |
| SCHEMBL401097 | 0.97 | IGF1R (0.94) | IGF1RCYP3A4MAPK3MAPK1MAPK6 | |
| SCHEMBL10225527 | 0.97 | IGF1R (0.94) | IGF1RCYP3A4MAPK3MAPK1MAPK6 | |
| SCHEMBL13842374 | 0.93 | IGF1R (0.86) | IGF1RCYP3A4MAPK3MAPK1MAPK6 | |
| SCHEMBL15131959 | 0.92 | IGF1R (0.87) | IGF1RCYP3A4MAPK3MAPK1MAPK6 | |
| SCHEMBL10225456 | 0.92 | IGF1R (1.00) | IGF1RCYP3A4MAPK3MAPK1MAPK6 | |
| SCHEMBL13447956 | 0.92 | IGF1R (1.00) | IGF1RCYP3A4MAPK3MAPK1MAPK6 | |
| SCHEMBL10225484 | 0.92 | IGF1R (1.00) | IGF1RCYP3A4MAPK3MAPK1MAPK6 | |
| SCHEMBL13812441 | 0.92 | IGF1R (1.00) | IGF1RCYP3A4MAPK3MAPK1MAPK6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739392-A1 | METHODS OF TREATING ACTIVE AND CHRONIC THYROID EYE DISEASE | Viridian Therapeutics, Inc. (US) | 2026-05-13 | — | — | EP | claimed |
| WO-2025014774-A9 | METHODS OF TREATING ACTIVE AND CHRONIC THYROID EYE DISEASE | Viridian Therapeutics, Inc. (US) | 2025-03-06 | — | — | WO | claimed |
| WO-2025014774-A1 | METHODS OF TREATING ACTIVE AND CHRONIC THYROID EYE DISEASE | Viridian Therapeutics, Inc. (US) | 2025-01-16 | — | — | WO | claimed |
| WO-2026106912-A1 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2026-05-21 | — | — | WO | disclosed |
| EP-4743080-A2 | METHODS OF TREATING A RAS RELATED DISEASE OR DISORDER | Revolution Medicines, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-4739392-A1 | METHODS OF TREATING ACTIVE AND CHRONIC THYROID EYE DISEASE | Viridian Therapeutics, Inc. (US) | 2026-05-13 | — | — | EP | disclosed |
| WO-2026090245-A1 | USE OF RAS INHIBITORS FOR TREATING CANCER | Revolution Medicines, Inc. (US) | 2026-04-30 | — | — | WO | disclosed |
| WO-2026090116-A2 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2026-04-30 | — | — | WO | disclosed |
| WO-2026090127-A1 | METHODS OF TREATING A RAS PROTEIN-RELATED DISEASE OR DISORDER | Revolution Medicines, Inc. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260108528-A1 | METHODS OF TREATING A RAS PROTEIN-RELATED DISEASE OR DISORDER | REVOLUTION MEDICINES INC (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4704850-A1 | COMBINATION THERAPY FOR A RAS RELATED DISEASE OR DISORDER | Revolution Medicines, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| WO-2025080946-A2 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2025-04-17 | — | — | WO | disclosed |
| WO-2025014774-A9 | METHODS OF TREATING ACTIVE AND CHRONIC THYROID EYE DISEASE | Viridian Therapeutics, Inc. (US) | 2025-03-06 | — | — | WO | disclosed |
| US-20250049810-A1 | METHODS OF TREATING A RAS PROTEIN-RELATED DISEASE OR DISORDER | Revolution Medicines, Inc. | 2025-02-13 | — | — | US | disclosed |
| WO-2025034702-A1 | RMC-6291 FOR USE IN THE TREATMENT OF RAS PROTEIN-RELATED DISEASE OR DISORDER | Revolution Medicines, Inc. (US) | 2025-02-13 | — | — | WO | disclosed |
| US-20250041295-A1 | METHODS OF TREATING A RAS RELATED DISEASE OR DISORDER | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2025-02-06 | — | — | US | disclosed |
| WO-2025019318-A2 | METHODS OF TREATING A RAS RELATED DISEASE OR DISORDER | Revolution Medicines, Inc. (US) | 2025-01-23 | — | — | WO | disclosed |
| WO-2025014774-A1 | METHODS OF TREATING ACTIVE AND CHRONIC THYROID EYE DISEASE | Viridian Therapeutics, Inc. (US) | 2025-01-16 | — | — | WO | disclosed |
| WO-2024229406-A1 | COMBINATION THERAPY FOR A RAS RELATED DISEASE OR DISORDER | Revolution Medicines, Inc. (US) | 2024-11-07 | — | — | WO | disclosed |
| WO-2024206858-A1 | COMPOSITIONS FOR INDUCING RAS GTP HYDROLYSIS AND USES THEREOF | Revolution Medicines, Inc. (US) | 2024-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250049810-A1 | METHODS OF TREATING A RAS PROTEIN-RELATED DISEASE OR DISORDER | KRAS, HRAS, NRAS | IGF1R 3389/4885CYP3A4 4884/4885MAPK3 486/4885 |
| US-20250041295-A1 | METHODS OF TREATING A RAS RELATED DISEASE OR DISORDER | KRAS, NRAS, HRAS | IGF1R 2979/4885CYP3A4 4785/4885MAPK3 321/4885 |
| US-20260108528-A1 | METHODS OF TREATING A RAS PROTEIN-RELATED DISEASE OR DISORDER | KRAS, NRAS, RAB1A | IGF1R 3369/4885CYP3A4 3253/4885MAPK3 1131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.